Fulgent Genetics, Inc. (FLGT)
| Market Cap | 519.98M |
| Revenue (ttm) | 277.76M |
| Net Income (ttm) | -164.97M |
| Shares Out | 30.59M |
| EPS (ttm) | -5.50 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 264,133 |
| Open | 16.70 |
| Previous Close | 16.71 |
| Day's Range | 16.56 - 17.40 |
| 52-Week Range | 16.56 - 30.68 |
| Beta | 1.51 |
| Analysts | Hold |
| Price Target | 28.50 (+67.65%) |
| Earnings Date | Nov 8, 2024 |
About FLGT
Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to h... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for FLGT stock is "Hold." The 12-month stock price forecast is $28.5, which is an increase of 67.65% from the latest price.
News
Fulgent Genetics, Inc. (FLGT) Q3 2024 Earnings Call Transcript
Fulgent Genetics, Inc. (NASDAQ:FLGT) Q3 2024 Earnings Conference Call November 8, 2024 8:30 AM ET Company Participants Melanie Solomon - Investor Relations Ming Hsieh - Chairman, Chief Executive Offi...
Fulgent Reports Third Quarter 2024 Financial Results
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeuti...
Fulgent to Participate in Upcoming Conferences
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ:FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic...
Fulgent Genetics Awarded Contract by the U.S. Department of Veterans Affairs to Provide Hereditary Cancer, Pharmacogenetic and Other Genetic Testing to Veterans1
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeuti...
Fulgent to Announce Third Quarter 2024 Financial Results on Friday, November 8, 2024
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic...
Fulgent Genetics: An NCAV Pick With Profit And Growth Potential
Fulgent Genetics is transitioning from a diagnostic business to a fully integrated healthcare company, with a focus on oncology. Despite past reliance on COVID-19 test revenues, Fulgent's core busines...
Fulgent Genetics: Core Growth Re-Acceleration Will Be The Critical Catalyst
Fulgent Genetics' core revenue grew just 3% in H1 2024, with full-year guidance of $280 million implying a step-up to 11% growth in H2 and 7% for FY 2024. Growth in precision diagnostics (+35% in H1 2...
Fulgent Genetics, Inc. (FLGT) Q2 2024 Earnings Call Transcript
Fulgent Genetics, Inc. (NASDAQ:FLGT) Q2 2024 Earnings Conference Call August 2, 2024 8:30 AM ET Company Participants Melanie Solomon - Investor Relations Ming Hsieh - Chief Executive Officer Brandon ...
Fulgent Reports Second Quarter 2024 Financial Results
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeuti...
Fulgent to Announce Second Quarter 2024 Financial Results on Friday, August 2, 2024
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic...
Press release Biocartis NV: Biocartis Welcomes Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as VP Global Marketing
PRESS RELEASE - 10/06/2024, 07:00 CEST Biocartis Welcomes Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as VP Global Marketing Mechelen, Belgium 10 June 2024 – Biocartis NV (the...
Fulgent Genetics: Growth Is Returning
Today, we put diagnostic company Fulgent Genetics, Inc. back in the spotlight as sales growth is returning after navigating a "Covid Cliff." While the company is still losing money, the stock is tradi...
Fulgent Data at ASCO 2024 Highlights Antitumor Activity from Lead Therapeutic Oncology Candidate, FID-007, in Head and Neck Cancer
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Pharma, a subsidiary of Fulgent Genetics, Inc. (NASDAQ: FLGT) and a leading nanobiotechnology company specializing in innovative cancer therapeutics, today a...
Fulgent Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2024 Annual Meeting
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Pharma, a subsidiary of Fulgent Genetics, Inc. (NASDAQ: FLGT) and a leading nanobiotechnology company specializing in innovative cancer therapeutics, today a...
Moffitt Cancer Center and Fulgent Pharma Join Forces to Revolutionize Cancer Therapeutics
TAMPA, Fla. & LOS ANGELES--(BUSINESS WIRE)--Moffitt Cancer Center, a world-renowned cancer treatment and research center, and Fulgent Pharma, a subsidiary of Fulgent Genetics, Inc. (NASDAQ: FLGT) and ...
Fulgent Genetics, Inc. (FLGT) Q1 2024 Earnings Call Transcript
Fulgent Genetics, Inc. (NASDAQ:FLGT) Q1 2024 Earnings Call Transcript May 3, 2024 8:30 AM ET Company Participants Melanie Solomon - IR Ming Hsieh - CEO Brandon Perthuis - CCO Paul Kim - CFO Conferenc...
Fulgent Reports First Quarter 2024 Financial Results
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeuti...
Fulgent Genetics to Announce First Quarter 2024 Financial Results on Friday, May 3, 2024
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic...
Fulgent Genetics (FLGT) Q4 2023 Earnings Call Transcript
Fulgent Genetics (FLGT) Q4 2023 Earnings Call Transcript
Fulgent Reports Fourth Quarter and Full Year 2023 Financial Results
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeuti...
Fulgent Genetics: Buy Growth Ahead Below Liquidation Value
Fulgent Genetics spent the past 2 years digesting the Covid cliff, which wiped out 80% of its market capitalization since the 2021 peak. The company is about to hit an inflection point, as 2024 will b...
Fulgent Genetics to Announce Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 28, 2024
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic...
Cord Blood Registry® (CBR®) by CooperSurgical® and Fulgent Genetics Launch Innovative Genetic Testing
Testing offers CBR families the opportunity to proactively seek additional information about their child's health TRUMBULL, Conn. and EL MONTE, Calif.
Fulgent to Participate in the Piper Sandler 35th Annual Healthcare Conference
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic...
Fulgent Shares Data from Two Poster Presentations at SITC 2023 Annual Meeting
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic...